Venous thrombosis is a chronic disease with a recurrence rate of approximately 30% within 5-8 years. The optimal duration of secondary thromboprophylaxis in these patients entails balancing the risk of recurrence against the risk of treatment-associated bleeding...
Keywords: Venöse Thrombose, Rezidiv, sekundäre Thromboseprophylaxe, Vitamin-K-Antagonisten, Risikofaktoren
01/2006 | Hämostaseologie, SchattauerAims: c-erbB-2 overexpression has been shown to be a potential marker of aggressive biological behaviour in a varity of tumours, whereas its role played in thyroid papillary thyroid carcinoma (PTC) remains unclear...
Keywords: Papilläres Schilddrüsenkarzinom, c-erbB-2, Her-2/neu, Rezidiv, Onkogene
01/2005 | Nuklearmedizin, SchattauerRecent trials on secondary prophylaxis after venous thromboembolism (VTE) have provided a wealth of data on the risk factors for recurrence and, to some extent, also for bleeding...
Keywords: Venous thromboembolism, risk factors, recurrence, bleeding
09/2006 | Thrombosis and Haemostasis, Schattauer
Keywords: bladder cancer, hTERT, real time RT-PCR, recurrence, tankyrase, telomere, voided urine
07/2007 | Clinical Chemical Laboratory Medicine, Walter de GruyterKeywords: Doppler, placenta, preeclampsia, pregnancy, recurrence, uterine artery
09/2004 | Journal of Perinatal Medicine, Walter de Gruyter